PharmaEssentia Corporation
6446
Clasificación en acciones
#1442
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Precio por acción
$36.89
Capitalización bursátil
$15.25B
Cambio (1 día)
-1.28%
Cambio (1 año)
144.12%
País
TW
Comercio PharmaEssentia Corporation (6446)
Categoría
Healthcare
Ratio P/B de PharmaEssentia Corporation (6446)
Ratio P/B al October 2026 TTM: 13.50
Según los informes financieros más recientes y el precio de las acciones de PharmaEssentia Corporation, el ratio P/B actual (TTM) es 13.50. Al final de 2023, el ratio P/B era 4.70.
Historial del ratio P/B de PharmaEssentia Corporation desde 2010 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 13.50 | 85.23% |
| 2024 | 7.29 | 54.92% |
| 2023 | 4.70 | -57.85% |
| 2022 | 11.16 | -36.95% |
| 2021 | 17.70 | 205.50% |
| 2020 | 5.79 | -44.22% |
| 2019 | 10.39 | -30.22% |
| 2018 | 14.88 | 65.96% |
| 2017 | 8.97 | 16.17% |
| 2016 | 7.72 | -85.09% |
| 2015 | 51.79 | 198.70% |
| 2014 | 17.34 | 0.82% |
| 2013 | 17.20 | -64.44% |
| 2012 | 48.36 | -92.11% |
| 2011 | 613.14 | 490.71% |
| 2010 | 103.80 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -62.67% |
IN
|
